vimarsana.com
Home
Live Updates
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS : vimarsana.com
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30...
Related Keywords
United States ,
Canada ,
Robert Jaffe ,
Flovent Diskus ,
Andas To Chartwell Inc ,
Glaxosmithkline ,
Lannett Company ,
Cediprof Inc ,
Prnewswire Lannett Company Inc ,
Boehringer Ingelheim ,
Exchange Commission ,
Recro Gainesville ,
Lannett Company Inc ,
Robert Jaffe Co ,
Financial Highlights ,
Gross Margin Better ,
Major Elements ,
Biosimilar Insulin Glargine Clinical Trial Over ,
Top Line Results Anticipated ,
Year End ,
First Half ,
Biosimilar Insulin Aspart ,
Product On Track ,
Early Next Calendar Year ,
Commence Pilot ,
Mesalamine Delayed Release Tablets ,
Tim Crew ,
Pipeline Update Subject ,
Biologics License Application ,
Cost Reduction ,
Quarter Financial Results ,
Year Financial Results ,
Call Information ,
Private Securities Litigation Reform Act ,
Biologics License Applications ,
Chief Information Officer ,
vimarsana.com © 2020. All Rights Reserved.